BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11505079)

  • 1. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
    Elhasid R; Lanir N; Sharon R; Weyl Ben Arush M; Levin C; Postovsky S; Ben Barak A; Brenner B
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):367-70. PubMed ID: 11505079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
    Harlev D; Zaidman I; Sarig G; Ben Arush MW; Brenner B; Elhasid R
    Thromb Res; 2010 Aug; 126(2):93-7. PubMed ID: 20546854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
    Malhotra P; Jain S; Kapoor G
    J Pediatr Hematol Oncol; 2018 Oct; 40(7):e450-e453. PubMed ID: 29554021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
    Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
    J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K; Minden M; Chan SM; Gupta V; Murphy T; Sakurai N; Atenafu EG; Brandwein JM; Seki JT
    Br J Haematol; 2020 Dec; 191(5):748-754. PubMed ID: 32395867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.
    Bhatt MD; Parmar N; Fowler JA; Chan AKC; Athale UH
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27483. PubMed ID: 30362248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
    Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
    Appel IM; Hop WC; Pieters R
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
    Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
    Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
    Goyal G; Bhatt VR
    Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
    Mitchell L; Lambers M; Flege S; Kenet G; Li-Thiao-Te V; Holzhauer S; Bidlingmaier C; Frühwald MC; Heller C; Schmidt W; Pautard B; Nowak-Göttl U
    Blood; 2010 Jun; 115(24):4999-5004. PubMed ID: 20339086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
    Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
    BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
    Brenner B; Hoffman R; Blumenfeld Z; Weiner Z; Younis JS
    Thromb Haemost; 2000 May; 83(5):693-7. PubMed ID: 10823264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
    Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
    Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
    Völler S; Pichlmeier U; Zens A; Hempel G
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):305-314. PubMed ID: 29204688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
    Lee JH; Lee J; Yhim HY; Oh D; Bang SM
    J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.